Initiating factors in perineuronal cell hyperplasia associated with chromatolytic neurons

Summary Neuronal hypertrophy and increased metabolism in nerve cells are evaluated as possible factors initiating hyperplasia of perineuronal cells. Colchicine induced neuropathy in the dorsal root ganglia is used as the model of increased neuronal metabolism.Twenty-eight female white rats weighing 100 g were divided into four groups, each animal receiving a 50 l injection into the subarachnoid space at the lumbosacral level eight days and again three days before sacrifice. The 50 l contained 25, 2.5 and 0.25 g of colchicine in distilled water for the first three groups and normal saline for the last group.A Zeiss ocular with random test points was used to determine the volume of tissue occupied by perineuronal cells and nerve cells in spinal ganglia. Direct cell counts yielded the size of the population of perineuronal cells and neurons.Irreversible motor and sensory loss occurred with the high dose injection, reversible loss with the 2.5 g injection and no loss with either the low dose or the saline injection. Chromatolytic neurons were noted in all animals receiving colchicine. Neither proliferation of perineuronal cells nor neuronal hypertrophy were observed. Neuronal hypertrophy, rather than altered neuronal metabolism, may be the initiating event in the perineuronal cell hyperplasia that frequently accompanies chromatolysis.     

The ultrastructure of nuclear division in a suctorian,Tokophrya infusionum

Summary Ultrastructural changes in the micro- and macronucleus throughout division were followed in synchronized cultures of the suctorian, Tokophrya infusionum. After an initial swelling, the micronucleus elongates enormously; microtubules within the micronucleus proliferate and lengthen as the micronucleus elongates. Changes in the macronucleus become visible only after micronuclear division is well underway. The chromatin bodies fuse into long chromatin strands, and the large bundles of microtubules present in the resting macronucleus break up into small groups which parallel the chromatin strands. Colchicine, which prevents reproduction in Tokophrya, seems to block division at a very early stage. The macronucleus appears the same as the resting nucleus of untreated organisms, with numerous microtubules and distinct chromatin bodies. The chromatin in the micronucleus aggregates into large clumps, however, and proliferation of microtubules does not occur.Supported by a Graduate Fellowship at The Rockefeller University.Supported by Grant A1-01407-12 USPHS and Grant A1-08989-01 USPHS.     

CRF-containing neurons of the rat hypothalamus

Summary The immunoreactive CRF-neurons of the rat hypothalamus have been examined immunohistochemically employing anti-rat CRF serum. These neurons are confined to the paraventricular nucleus, dorsomedial-lateral hypothalamic area, and suprachiasmatic nucleus, and are, respectively, also immunoreactive to anti-Met-enk, -alpha-MSH, and -VIP sera. Intraventricular administration of colchicine (50 g/5 l/rat) induces a dramatic enhancement of the immunostainability of the cell somata, and also accelerates the development of immunoreactivity of other stored peptides, especially in the paraventricular nucleus.The CRF-neurons respond to adrenalectomy by showing increased immunoreactivity and an increase in the number of cell bodies; in the dorsomedial-lateral area and suprachiasmatic nucleus, there is also an enhanced immunoreactivity for alpha-MSH and VIP, respectively. CRF-cells in the paraventricular nucleus become markedly hypertrophied, but do not show any enhanced immunoreactivity for Met-enk. Since the axons of the paraventricular neurons run to the median eminence, it is probable that they are involved with the endocrine control of hypophysial ACTH release. It is concluded that the CRF-containing neurons in rat hypothalamus consist of three types which are functionally and morphologically different.     

Concanavalin a capping of rhesus monkey polymorphonuclear leukocytes

The technique of capping, a probe designed to evaluate the fluidity and functional competence of human polymorphonuclear leukocytes (PMNs), has been successfully adapted for rhesus monkey PMNs. The capping characteristics of rhesus monkey PMNs are very similar to those of human PMNs. Utilizing this capping technique as an evaluation tool and with fetal/neonatal rhesus monkey as a functional animal model, the ontogeny of movement and chemotactic characteristics of PMNs can now be studied.     

Daily Variations in Colchicine‐Induced Apoptosis in Duodenal Crypts

Apoptotic cell death can be induced by several agents, among them colchicine, a microtubule disrupting‐drug that affects continuously renewing cell populations, such as the intestinal crypt enterocytes. The objectives of this investigation were (1) to confirm in vivo colchicines‐inductive effect and (2) to determine the existence of 24 h variations in the crypt enterocytes apoptotic indices. The study was done on C3H/S male adult mice housed under standardized conditions. Starting at midnight until the end of a circadian period, subgroups of mice were sacrificed after having been injected with colchicine or saline i.p. 4 h beforehand. Duodenal samples were processed for hematoxylin‐eosin staining and TUNEL technique. In order to score the number of apoptosis, the longitudinal sections of the crypts were divided into three regions comprised, respectively, of tiers 1–4, 5–12, and 13–20, proceeding from the bottom to the top of the crypt. Values of each lot were expressed as mean±SEM. A highly significant statistical difference in apoptotic indices was found for colchicine‐treated animals. The 24 h curve for colchicine‐induced apoptosis displayed qualitative and quantitative differences compared to other inducer agents. Highest apoptotic indices were found in the deepest crypt regions. Daily variations were observed in all the crypt sectors of the colchicine‐treated animals and in tiers 5–12 of the saline controls. The present work demonstrates that the colchicine cytotoxicity due to its apoptotic‐inducing effect depends on the dosing time during the 24 h in this mouse strain.     

Discovery of structurally simplified analogs of colchicine as an immunosuppressant

We have discovered a new class of colchicine-derived therapeutic agents for immune diseases including rejection of organ-transplantation and autoimmune disease. Compound 2, which had been developed to overcome poor pharmacokinetic properties of compound 1, a first-generation colchicine analog, turned out to show toxicity such as intestinal toxicity and loss of weight during in vivo tests. The deletion of 7-carboxamide group and middle ring-truncation in colchicine allowed us to have structurally simplified analogs with strong immunosuppressive activity. Herein, we report non-alkaloid tricyclic compound 7 and 12 as immunosuppressants which exhibited a strong immunosuppressive in vivo efficacy on the T-dependent antibody response, the Zymosan A-induced arthritis model and the Carrageenan-induced edema model. Compound 7 and 12 revealed less toxicity than the previous lead compound 2, and their minimum lethal doses (MLD) were proved to exceed 100 mg/kg.     

Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity

Conventional chemotherapy has undesirable toxic side-effects to healthy tissues due to low cell selectivity of cytotoxic drugs. One approach to increase the specificity of a cytotoxic drug is to make a less toxic prodrug which becomes activated at the tumour site. The cysteine protease legumain have remarkable restricted substrate specificity and is the only known mammalian asparaginyl (Asn) endopeptidase. Over-expression of legumain is reported in cancers and unstable atherosclerotic plaques, and utilizing legumain is a promising approach to activate prodrugs.In this study we have synthesized the legumain-cleavable peptide sequence N-Boc-Ala-Ala-Asn-Val-OH. The peptide was subsequently conjugated to deacetyl colchicine during three steps to produce Suc-Ala-Ala-Asn-Val-colchicine (prodrug) with >90% chemical purity. Several cell lines with different expressions and activities of legumain were used to evaluate the general toxicity, specificity and efficacy of the microtubule inhibitor colchicine, valyl colchicine and the legumain-cleavable colchicine prodrug. The prodrug was more toxic to the colorectal cancer HCT116 cells (expressing both the 36 kDa active and 56 kDa proform of legumain) than SW620 cells (only expressing the 56 kDa prolegumain) indicating a relationship between toxicity of the prodrug and activity of legumain in the cells. Also, in monoclonal legumain over-expressing HEK293 cells the prodrug toxicity was higher compared to native HEK293 cells. Furthermore, co-administration of the prodrug either with the potent legumain inhibitor cystatin E/M or the endocytosis inhibitor Dyngo-4a inhibited cell death, indicating that the prodrug toxicity was dependent on both asparaginyl endopeptidase activity and endocytosis. This colchicine prodrug adds to a legumain-activated prodrug strategy approach and could possibly be of use both in targeted anticancer and anti-inflammatory therapy.     

The efficacy of new colchicine derivatives and viability of the T-Lymphoblastoid cells in three-dimensional culture using F MRI and HPLC-UV ex vivo

The paper describes ex vivo applications of colchicine derivatives for the treatment of human T-Lymphoblastoid (CEM) cells. Moreover, the role of the substitutions of ring A at C-1 and C-7 side chain of colchicine analogues was probed by the synthesis and examination of their effects on the three-dimensional (3-D) CEM cells’ growth. The CEM cells were cultured in the hollow fiber bioreactor (HFB) device. We used ¹H and ¹⁹F magnetic resonance imaging (MRI) to monitor changes in 3-D CEM cell culture. ¹⁹F MRI was used for visualization of the cellular uptake of new fluorine derivatives. Before and after treatment CEM cells profile was investigated with high performance liquid chromatography (HPLC-UV).     

利用染色体G显带技术鉴定人永生细胞实验条件初探

目的:探索利用染色体G显带技术鉴定人永生淋巴细胞的最佳实验条件。方法:在常规染色体制片技术的方法和手段的基础上,分别观察不同PHA浓度和培养时间对永生淋巴细胞分裂增殖的影响;然后,选择不同浓度秋水仙素处理细胞,观察染色体分散程度和中期分裂相的形态。结果:在永生淋巴细胞培养48h,PHA终浓度为0.1mg/mL,秋水仙素终浓度为0.04μg/mL,且其作用时间为1.5~2h的条件下,所获得的细胞染色体标本分裂相较多、染色体较长、分散较好、利于带型分析。结论:利用染色体G显带技术鉴定人永生淋巴细胞提供了技术保证,降低了实验成本,并且缩短了实验时间。